Background
Methods
Study populations
CCP2 assay and measurement of ACPA fine specificities and isotypes
Peptide synthesis
ELISA assays
Cut-off values and specificity control
Statistical analysis
Results
Patient characteristics
PR (n = 54) | RA (n = 54) |
p
| |
---|---|---|---|
Female, n (%) | 34 (62.9) | 34 (62.9) | NS |
Age (year), mean ± SD | 51.2 ± 11.3 | 54.7 ± 11.8 | NS |
Disease duration (years), mean ± SD | 11.6 ± 10.7 | 8.3 ± 6.1 | NS |
RF n (%) | 31 (57.4) | 30 (55.6) | NS |
RF levelsa, mean ± SD | 237.3 ± 300.6 | 379.6 ± 715.9 | NS |
CCP2 n (%) | 36 (66.7) | 36 (66.7) | NS |
CCP2 levelsa, mean ± SD | 392.6 ± 527.6 | 487.4 ± 584.4 | NS |
IgG ACPA fine specificities
IgG | IgM | IgA | Any isotype [+] | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
PR (n = 54) | RA (n = 54) |
p
| PR (n = 54) | RA (n = 54) |
P
| PR (n = 54) | RA (n = 54) |
P
| PR (n = 54) | RA (n = 54) |
p
| |
p18 α-fibrin, n (%) | 19 (35.2) | 26 (48.1) | 0.17 | 7 (13) | 21 (38.9) |
0.02
| 10 (18.5) | 27 (50) |
<0.001
| 28(51.9%) | 37(68.5%) | 0.077 |
p55 vimentin, n (%) | 13 (24.1) | 32 (59.3) |
<0.001
| 5 (9.3) | 5 (9.3) | 1 | 9 (16.7) | 21(38.9) |
0.01
| 22(40.7%) | 40 (74.1%) |
<0.001
|
CEP-1 Enolase, n (%) | 16 (29.6) | 20 (37.0) | 0.37 | 1 (1.8%) | 0 (0) | (0.3) | 1 (1.8) | 3(5.6) | 0.3 | 17(31.5%) | 22(40.7%) | 0.317 |
p48 vimentin, n (%) | 1(1.9) | 8 (14.8) |
0.03
| – | – | – | – | – | – | – | – | – |
PR | RA |
p
| |
---|---|---|---|
0 | 23 (42.6%) | 12 (22.2%) |
0.024
|
1 | 17 (31.5%) | 17 (31.5%) | 1 |
2 | 10 (18.5%) | 15 (27.8%) | 0.25 |
3 | 4 (7.4%) | 10 (18.5%) | 0.08 |
≥2 | 14 (25.9%) | 25 (46.3%) |
0.028
|